AZMARDA 50MG (Sacubitril (24mg) + Valsartan (26mg))

AZMARDA 50MG is a medication prescribed to patients that combines two active ingredients: Sacubitril at a dosage of 24mg and Valsartan at 26mg. This formulation is classified as an Angiotensin Receptor-Neprilysin Inhibitor (ARNI), utilized primarily for managing chronic heart failure with reduced ejection fraction (HFrEF) in adults. The medication may also be appropriate for children aged 1 year and older in certain situations. The primary goal of AZMARDA 50MG is to lower the risk of cardiovascular mortality and hospitalization due to heart failure. Chronic heart failure is a serious condition characterized by the heart’s inability to effectively pump blood, which can lead to symptoms such as breathlessness, fatigue, and swelling in various body parts. AZMARDA 50MG aims to enhance the heart’s pumping efficiency, relieve symptoms, and improve overall outcomes for those affected. This specific dosage serves as either an introductory or a lower maintenance dose, allowing healthcare providers to assess the patient’s reactions before considering an increase to a higher dosage, such as AZMARDA 100mg or 200mg, if necessary. The effectiveness of AZMARDA 50MG arises from the synergistic action of its two components, which work through different but complementary mechanisms to address the factors contributing to heart failure. Use this medicine only under medical supervision. Follow the dose and schedule exactly as advised. Do not stop abruptly without guidance. Keep a record of any unusual symptoms and share them with your clinician. Combine therapy with appropriate lifestyle measures and routine monitoring as recommended.